In this issue, eight major achievements of national medicine were selected, and eight core scientific research breakthroughs were disassembled, including neuroblastoma, KRAS mutant solid tumor, fundus
The tide of medical and health innovation is surging, and high-quality innovation projects are the core driving force of industry development and the focus of capital
On May 6th, the National Medical Products Administration (NMPA) officially approved the world’s first CDK2/4/6 inhibitor, Coumoxili Capsules (Saitanxin), independently developed by China’s biopharmaceutical subsidiary, Zhengda
This week, there are various hot topics in the financing of the medical and health field. Ganewei Medical’s multi hundred million yuan C-round enhanced tumor ablation
· Guangxi Holds Expert Review Meeting on Patent Regulations Revision · Lex Machina Releases 2026 Class Action Litigation Report · BMW's US Patent Dispute in Germany
Current biopharmaceutical financing updates: Nuanxin Jia has completed a strategic financing of 300 million yuan, leading the field of visual brain computer interfaces; Intelligent Diagnosis Technology’s
In the increasingly fierce competition for intellectual property, the speed of patent layout directly affects the market share advantage. For innovative enterprises, choosing the appropriate review
· Fujian Releases 2025 Provincial Intellectual Property Protection Typical Cases · Germany's Court Rules: AI-Generated Designs Not Protected by Copyright · USPTO Releases New Procedure for
At present, the wave of innovation in the medical and health field continues to surge, and cutting-edge technologies continue to inject new vitality into clinical diagnosis
This issue selects nine top issues to highlight scientific research achievements, focusing on nine frontier directions: clinical progress of innovative drugs for liver diseases, hemostatic and